Schnitzler syndrome is a rare autoinflammatory disorder that is characterized by chronic urticarial rash and monoclonal gammopathy. It was first described by Dr. Liliane Schnitzler in 1972, and since then, the understanding of the disease has grown significantly. The syndrome is often misdiagnosed, which leads to delayed treatment and can result in significant morbidity. In this essay, we will discuss the clinical features, pathophysiology, diagnosis, and management of Schnitzler syndrome.
Clinical Features of Schnitzler Syndrome
The hallmark of Schnitzler syndrome is a chronic urticarial rash, which is often described as pruritic and recurrent. The rash is usually non-specific, and it can appear on any part of the body, but it is often seen on the trunk and limbs. The rash typically lasts for more than six weeks, and it can be associated with fever, joint pain, and fatigue. Patients with Schnitzler syndrome can also present with bone pain, which is often located in the long bones of the extremities. The bone pain can be severe, and it can lead to fractures in some cases.
Schnitzler syndrome is also associated with monoclonal gammopathy, which is characterized by the presence of a monoclonal immunoglobulin in the blood. The monoclonal gammopathy is usually of the IgM subtype, and it is often found in the serum and/or urine of patients with Schnitzler syndrome. The presence of monoclonal gammopathy is a distinguishing feature of Schnitzler syndrome, and it is not seen in other forms of chronic urticaria.
Pathophysiology of Schnitzler Syndrome
The pathophysiology of Schnitzler syndrome is not fully understood, but it is thought to be related to abnormal activation of the immune system. The exact mechanism of immune dysregulation is not known, but it is believed to involve the innate immune system, specifically the inflammasome pathway. The inflammasome pathway is responsible for the production of cytokines, which are involved in the regulation of inflammation. Abnormal activation of the inflammasome pathway can lead to the production of pro-inflammatory cytokines, which can cause tissue damage and inflammation.
Another possible mechanism for the pathogenesis of Schnitzler syndrome is the activation of the adaptive immune system. It has been suggested that the monoclonal gammopathy seen in Schnitzler syndrome is the result of clonal expansion of B-cells, which are responsible for the production of immunoglobulins. The expansion of B-cells can lead to the production of autoantibodies, which can bind to self-antigens and cause tissue damage.
Diagnosis of Schnitzler Syndrome
The diagnosis of Schnitzler syndrome can be challenging, and it often requires the exclusion of other causes of chronic urticarial rash. The diagnosis is based on clinical criteria, and the presence of monoclonal gammopathy is a key diagnostic feature. The clinical criteria for the diagnosis of Schnitzler syndrome are as follows:
- Recurrent urticarial rash for more than six weeks
- At least two of the following symptoms: fever, bone pain, joint pain, and/or fatigue
- The presence of monoclonal gammopathy, usually of the IgM subtype
Other laboratory tests that can be useful in the diagnosis of Schnitzler syndrome include:
- Complete blood count (CBC) to evaluate for leukocytosis and/or anemia
- Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) to assess for inflammation
- Liver function tests (LFTs) to evaluate for liver involvement
- Renal function tests (RFTs) to assess for kidney involvement
- Serum protein electrophoresis (SPEP) to detect the presence of monoclonal gammopathy
- Immunofixation electrophoresis (IFE) to determine the subtype of monoclonal gammopathy.
Schnitzler syndrome is a rare disease, with an estimated prevalence of less than 1 per million individuals. The disease affects both men and women equally, and it typically presents in middle-aged individuals, with a mean age of onset of 51 years. However, cases of Schnitzler syndrome have been reported in individuals as young as 17 years and as old as 83 years.
Schnitzler syndrome is a sporadic disorder, meaning it is not inherited in a familial pattern. However, some cases of Schnitzler syndrome have been reported in families, suggesting a possible genetic predisposition. In one study, a genetic variant in the NLRP3 gene, which is involved in the inflammasome pathway, was identified in a small number of patients with Schnitzler syndrome. However, this variant was not found in all patients with the disease, suggesting that other genetic and environmental factors may also be involved in the pathogenesis of the disease.
Schnitzler syndrome is a rare disease, and the true incidence and prevalence are not well-established due to underdiagnosis and misdiagnosis. The disease is often misdiagnosed as chronic urticaria or other forms of autoimmune disease, leading to delays in diagnosis and treatment. Improved awareness of the disease among clinicians and the availability of specific diagnostic criteria may help to improve the diagnosis of Schnitzler syndrome and increase our understanding of the epidemiology of the disease.
The differential diagnosis of Schnitzler syndrome includes other causes of chronic urticarial rash, as well as other conditions that can present with fever, joint pain, and monoclonal gammopathy. The following are some of the conditions that should be considered in the differential diagnosis of Schnitzler syndrome:
Chronic urticaria: Chronic urticaria is a common condition characterized by recurrent episodes of urticarial rash that lasts for more than six weeks. Unlike Schnitzler syndrome, chronic urticaria is not associated with monoclonal gammopathy.
Urticarial vasculitis: Urticarial vasculitis is a condition characterized by urticarial rash that is associated with inflammation of blood vessels. The rash in urticarial vasculitis is often more persistent and may be associated with purpura or petechiae.
Cryoglobulinemia: Cryoglobulinemia is a condition characterized by the presence of abnormal proteins called cryoglobulins in the blood. Cryoglobulins can cause inflammation of blood vessels, leading to a range of symptoms, including urticaria, joint pain, and fever.
Mastocytosis: Mastocytosis is a condition characterized by the abnormal accumulation of mast cells in various tissues, leading to the release of histamine and other inflammatory mediators. Mastocytosis can present with urticarial rash, joint pain, and fatigue, but it is not associated with monoclonal gammopathy.
Autoimmune diseases: Autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjogren’s syndrome can present with fever, joint pain, and monoclonal gammopathy. However, these conditions are typically associated with specific autoantibodies and other laboratory abnormalities that can help to distinguish them from Schnitzler syndrome.
Lymphoproliferative disorders: Lymphoproliferative disorders such as Waldenstrom’s macroglobulinemia and multiple myeloma can present with monoclonal gammopathy and bone pain, which can be similar to the symptoms seen in Schnitzler syndrome. However, these conditions are typically associated with other laboratory abnormalities, such as elevated levels of immunoglobulin and abnormal bone marrow biopsy findings.
It is important to distinguish Schnitzler syndrome from these other conditions, as the treatment and prognosis can be significantly different. The diagnosis of Schnitzler syndrome is based on clinical criteria and the presence of monoclonal gammopathy, which is a key distinguishing feature of the disease. Further testing, including laboratory tests and skin biopsy, may be necessary to rule out other conditions in the differential diagnosis.
Complications of Schnitzler syndrome can include osteoporosis, bone fractures, and lymphoproliferative disorders. Patients with Schnitzler syndrome are also at increased risk of developing secondary amyloidosis, a condition in which abnormal proteins accumulate in organs such as the kidneys, liver, and heart.
Osteoporosis is a condition characterized by loss of bone mass and increased risk of bone fractures. Patients with Schnitzler syndrome are at increased risk of osteoporosis due to the chronic inflammation and bone pain associated with the disease. In one study, approximately 40% of patients with Schnitzler syndrome had evidence of osteoporosis on bone density scans.
Bone fractures are another potential complication of Schnitzler syndrome, particularly in patients with severe bone pain. Fractures can occur spontaneously or with minimal trauma, and they can lead to significant morbidity and disability.
Lymphoproliferative disorders, such as Waldenstrom’s macroglobulinemia and multiple myeloma, are another potential complication of Schnitzler syndrome. Patients with Schnitzler syndrome have an increased risk of developing these disorders, particularly if the monoclonal gammopathy is of the IgM subtype. In one study, approximately 15% of patients with Schnitzler syndrome developed lymphoproliferative disorders during a mean follow-up period of 10 years.
Secondary amyloidosis is a rare but serious complication of Schnitzler syndrome. In this condition, abnormal proteins called amyloid fibrils to accumulate in various organs, leading to organ dysfunction and failure. The risk of secondary amyloidosis is increased in patients with Schnitzler syndrome who have high levels of monoclonal immunoglobulin in the blood.
It is important for clinicians to be aware of these potential complications and to monitor patients with Schnitzler syndrome for signs of bone disease, lymphoproliferative disorders, and secondary amyloidosis. Early detection and treatment of these complications can help to improve outcomes and prevent further complications.
- Schnitzler L. “Lésions urticariennes chroniques permanentes (érythème pétaloide?) associées à un syndrome d’hypergam-maglobulinémie, de frissons récidivants, de pesanteur des jambes et d’arthralgies.” Ann Dermatol Venereol. 1972; 99: 877-888.
- Lipsker D, Veran Y, Grunenberger F, Cribier B, Heid E, Grosshans E. The Schnitzler syndrome: four new cases and review of the literature. Medicine (Baltimore). 2001;80(1):37-44. doi: 10.1097/00005792-200101000-00004. PMID: 11144050.
- de Koning HD, Bodar EJ, van der Meer JW, Simon A. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum. 2007;37(3):137-148. doi: 10.1016/j.semarthrit.2007.01.007. PMID: 17324545.
- Simon A, Asli B, Braun-Falco M, et al. Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy. 2013;68(5):562-568. doi: 10.1111/all.12137. PMID: 23521766.
- Gusdorf L, Lipsker D. Schnitzler syndrome: a review. Curr Opin Rheumatol. 2019;31(1):21-28. doi: 10.1097/BOR.0000000000000559. PMID: 30383520.